en Hematology Hematology Review Article Review Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14pt"><b><i><span style="color:blue">Background:</span></i></b> Although genetic mutations in additional sex-combs-like 1 (ASXL1) are prevalent in acute myeloid leukemia (AML), their exact impact on the AML prognosis remains uncertain. Hence, the present article was carried out to explore the prognostic importance of ASXL1 mutations in AML. </span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Methods</span></i></b><i><span style="color:blue">:</span></i> We thoroughly searched electronic scientific databases to find eligible papers. Twenty-seven studies with an overall number of 8,953 participants were selected for the current systematic review. The hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were extracted from all studies with multivariate or univariate analysis. Pooled HRs and p-values were also calculated as a part of our work.</span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Results</span></i></b><i><span style="color:blue">:</span></i> The pooled HR for OS in multivariable analysis indicated that ASXL1 significantly diminished survival in AML patients (pooled HR: 1.67; 95% CI: 1.342-2.091).</span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Conclusions:</span></i></b> ASXL1 mutations may confer a poor prognosis in AML. Hence, they may be regarded as potential prognostic factors. However, more detailed studies with different ASXL1 mutations are suggested to shed light on this issue.<b><i><span style="color:#0033cc"></span></i></b></span></span></span><br> &nbsp; Acute myeloid leukemia, Prognosis, Additional sex comb-like 1, ASXL1, ASXL1 mutation. 202 214 http://caspjim.com/browse.php?a_code=A-10-2544-2&slc_lang=en&sid=1 Maryam Sheikhi sheikhim75@gmail.com 100319475328460047846 100319475328460047846 No Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Mehrdad Rostami m.rostami9675@gmail.com 100319475328460047847 100319475328460047847 No Departments of Hematology and Blood Banking, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran Gordon Ferns G.Ferns@bsms.ac.uk 100319475328460047848 100319475328460047848 No Division of Medical Education, Brighton and Sussex Medical School, Brighton, United Kingdom Hossein Ayatollahi ayatollahih@mums.ac.ir 100319475328460047849 100319475328460047849 No Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Payam Siyadat payam.siyadat19899@gmail.com 100319475328460047850 100319475328460047850 No Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Yasamin Ayatollahi Ayat.yasamin@yahoo.com 100319475328460047851 100319475328460047851 No Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Zahra Khoshnegah zkhoshnegah@gmail.com 100319475328460047852 100319475328460047852 Yes Department of Laboratory Hematology and Blood Banking, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran